ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
21.637,53
0,93%
S&P 500
6.039,31
-0,47%
Dow Jones
44.713,52
-0,31%
Euro vs US Dollar
1,04147
-0,13%
Bitcoin
103.952,00
2,58%
Pepperstone
Advertisement
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. ImmunityBio Inc (IBRX)

  7. ImmunityBio Inc (IBRX) News

IBRX

ImmunityBio (IBRX)

ImmunityBio Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:IBRX
DatumZeitQuelleÜberschriftSymbolFirma
29/01/202514h30Business WireImmunityBio Announces Collaboration with BeiGene on Confirmatory Phase 3 Trial of ANKTIVA® and PD-1 Checkpoint Inhibitor Combination in Non-Small Cell Lung CancerNASDAQ:IBRXImmunityBio Inc
27/01/202515h00Business WireImmunityBio Announces European Medicines Agency Acceptance of Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In SituNASDAQ:IBRXImmunityBio Inc
25/01/202502h47Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IBRXImmunityBio Inc
15/01/202523h20Business WireImmunityBio Provides Regulatory Update on Anticipated FDA Submissions in 2025 Following Meeting with the AgencyNASDAQ:IBRXImmunityBio Inc
15/01/202523h20Business WireImmunityBio Provides Regulatory Update on Global Submission for ANKTIVA + BCG in BCG Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ in Europe and United KingdomNASDAQ:IBRXImmunityBio Inc
06/01/202515h00Business WireImmunityBio Announces Permanent J-code (J9028) for ANKTIVA® Is Now EffectiveNASDAQ:IBRXImmunityBio Inc
03/01/202522h54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IBRXImmunityBio Inc
12/12/202414h00GlobeNewswire Inc.D. Boral Capital Served as Co-Manager to ImmunityBio, Inc. (Nasdaq: IBRX) in connection with its $100.0 Million Underwritten Public OfferingNASDAQ:IBRXImmunityBio Inc
12/12/202412h45Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:IBRXImmunityBio Inc
11/12/202413h46Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IBRXImmunityBio Inc
11/12/202413h30Business WireImmunityBio, Inc. Announces Pricing of Public Offering of Common StockNASDAQ:IBRXImmunityBio Inc
10/12/202423h28Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IBRXImmunityBio Inc
10/12/202423h13Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:IBRXImmunityBio Inc
10/12/202422h24Business WireImmunityBio, Inc. Announces Proposed Public Offering of Common StockNASDAQ:IBRXImmunityBio Inc
21/11/202416h00PR Newswire (US)ImmunityBio and nCartes Enter Collaboration Agreement on Clinical Trial Data FulfillmentNASDAQ:IBRXImmunityBio Inc
19/11/202415h00PR Newswire (US)ImmunityBio, Inc. Investor Alert (NASDAQ: IBRX): Schubert Jonckheer & Kolbe LLP Investigating Potential Shareholder Claims Against the Company's Officers and Directors for Possible False StatementsNASDAQ:IBRXImmunityBio Inc
19/11/202414h01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IBRXImmunityBio Inc
19/11/202414h00Business WireImmunityBio Completes ANKTIVA’s Post-Approval Enrollment of the 100th Patient in BCG Unresponsive NMIBC CIS Trial and Reports a Complete Response Rate of 71% with a Durable Duration of Response Ranging Up to 54 MonthsNASDAQ:IBRXImmunityBio Inc
12/11/202413h30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IBRXImmunityBio Inc
12/11/202413h15Business WireImmunityBio Reports Third-Quarter 2024 Financial ResultsNASDAQ:IBRXImmunityBio Inc
24/10/202415h00Business WireFirst Patients Dosed in Phase 1 Clinical Study of ImmunityBio’s CAR-NK Cell Therapy for the Treatment of Relapsed B-Cell Non-Hodgkin LymphomaNASDAQ:IBRXImmunityBio Inc
21/10/202415h00Business WireImmunityBio to Participate in the Jefferies London Healthcare ConferenceNASDAQ:IBRXImmunityBio Inc
09/09/202414h30Business WireImmunityBio Presents Positive Long-Term Overall Survival Data in Non-Small Cell Lung Cancer Patients and Announces Registrational Intent Phase 3 Trials with ANKTIVA® and Checkpoint Immunotherapy at World Conference on Lung Cancer NASDAQ:IBRXImmunityBio Inc
12/08/202414h46Business WireImmunityBio’s ANKTIVA® Now Covered By More Than a Dozen Insurance Plans Representing Over 100 Million Lives Within Months of FDA ApprovalNASDAQ:IBRXImmunityBio Inc
12/08/202414h03Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IBRXImmunityBio Inc
06/08/202415h00Business WireImmunityBio Announces Study of ANKTIVA® in Combination with the AdHER2DC Cancer Vaccine as a Potential Therapy to Control Endometrial CancerNASDAQ:IBRXImmunityBio Inc
25/07/202417h02PR Newswire (US)Kuehn Law Encourages Investors of ImmunityBio, Inc. to Contact Law FirmNASDAQ:IBRXImmunityBio Inc
18/07/202403h48Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IBRXImmunityBio Inc
20/06/202415h00Business WireImmunityBio Announces Insurance Coverage of ANKTIVA® Across Multiple States with First Commercial Doses Administered Just Weeks After FDA Approval—Opening New Era for Immunotherapy Beyond Checkpoint InhibitorsNASDAQ:IBRXImmunityBio Inc
14/06/202400h50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IBRXImmunityBio Inc
 Showing the most relevant articles for your search:NASDAQ:IBRX

Kürzlich von Ihnen besucht

TG
A18044
United States of America
TSX
9162
Bleach
LSE
HWSS
Hsbc Msciwc Esg
NASDAQ
JANX
Janux Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2025 ADVFN PLC - Alle Rechte vorbehalten

Werbung entfernen

Melden Sie sich für ein werbefreies Erlebnis an

Keine Werbung

Versuchen Sie es jetzt

Anzeigen behalten